| Oct 31 |
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
|
| Oct 29 |
Immunic to Participate in Industry, Scientific and Investor Conferences in November
|
| Oct 22 |
Immunic late-stage program for lead asset to proceed as planned
|
| Oct 22 |
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
|
| Oct 9 |
Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ...
|
| Sep 18 |
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
|
| Sep 11 |
Owning 39% shares,hedge funds owners seem interested in Immunic, Inc. (NASDAQ:IMUX),
|
| Sep 4 |
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
|
| Aug 28 |
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
|
| Aug 9 |
Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript
|
